|
Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases
RECRUITINGSponsored by First Affiliated Hospital of Fujian Medical University
Actively Recruiting
SponsorFirst Affiliated Hospital of Fujian Medical University
Started2023-12-01
Est. completion2026-12-31
Eligibility
Age30 Years – 74 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07898904
Summary
68-Ga-DOTATATE is a radiotracer targeting somatostatin receptors (SSTR). In this study, we investigated the diagnostic efficacy of delayed \^68\^Ga-DOTATATE PET/MR in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and liver metastases, and performed a head-to-head comparison with conventional 68-Ga-DOTATATE PET/CT.
Eligibility
Age: 30 Years – 74 YearsHealthy volunteers accepted
Inclusion Criteria: (a)Histologically confirmed well-differentiated GEP-NETs via biopsy or surgical resection in adults aged 18-80 years,(b) confirmed or suspected liver metastases, as determined by previous imaging studies or PET/CT scans,(c) availability of comprehensive surgical reports, pathological findings, comparative data, and clinical follow-up outcomes for analysis,(d) absence of PET/MR contraindications , with voluntary participation and signed informed consent forms adhering to ethical and research guidelines Exclusion Criteria: (a) unavailability of surgical, pathological or long-term follow-up data; (b) non-compliance with age eligibility criteria or presence of comorbidities compromising protocol adherence
Conditions3
CancerGastroenteropancreatic Neuroendocrine TumorsLiver Cancer
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorFirst Affiliated Hospital of Fujian Medical University
Started2023-12-01
Est. completion2026-12-31
Eligibility
Age30 Years – 74 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07898904